Janney Capital Upgrades DepoMed Inc (DEPO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50
May 12, 2015 12:42 PM EDTRoth Capital analyst Scott Henry trimmed his price target on DepoMed Inc (NASDAQ: DEPO) to $28.50 (from $30.00) following Q1 results but maintained a Buy rating. The firm views today's 18% sell-off as a "over-reaction."
Henry commented, "DEPO reported 1Q15 results that were at the lower end... More
